(2004; 14 pages)
WHO Pharmaceuticals Newsletter 2004, No. 04
prepared in collaboration with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden
The aim of this Newsletter is to disseminate information on the safety and efficacy of pharmaceutical products, based on information received from our network of "drug information officers" and other sources such as specialized bulletins and journals, as well as partners in WHO. The information is produced in the form of résumés in English, full texts of which may be obtained on request from:
Quality Assurance and Safety:
World Health Organization,
1211 Geneva 27, Switzerland
E-mail address: email@example.com
Fax: +41 22 791 4730
Further information on adverse reactions may be obtained from the WHO Collaborating Centre for International Drug Monitoring, Stora Torget 3, S-753 20 Uppsala, Sweden
Internet:http://www.who-umc.org prepared in collaboration with the
WHO Collaborating Centre for
International Drug Monitoring,
Many countries in Africa are introducing combinations of antiretrovirals as a part of WHO's strategy to provide antiretroviral treatment to an additional three million people by 2005. Most of the needed first-line drugs are also available as multi-source generics. As with many of the newly registered products there is still limited experience with the operational use of antiretroviral drugs in general, especially in the different developing country settings. It is imperative that measures should be undertaken not only to guarantee the quality of the products but also to ensure proper monitoring of their safety and efficacy.
A workshop course is being organized by WHO in Pretoria, South Africa from 1 to 10 September for HIV/AIDS programme managers and officials responsible for pharmacovigilance in eight African countries (Kenya, Malawi, Mozambique, Nigeria, South Africa, Uganda, United Republic of Tanzania and Zambia). The programme for this workshop is included on page 8 of this issue.
The Annual Meeting of the National Centres participating in the WHO Programme for International Drug Monitoring will take place in October, in Dublin. The theme of this meeting is "Pharmacovigilance and focused surveillance methods" (draft agenda on page 10). This will be followed by the annual meeting of the International Society of Pharmacovigilance, also in Dublin. We hope to see many of you at one or both of these meetings.
We have now established a list of e-mail addresses for electronic mailing of the newsletter to our readers. You can join this list by sending your e-mail details to firstname.lastname@example.org.